NCT04183764

MAX-40279-01 in Patients With Advanced Solid Tumors

A Phase Ⅰ Study for Safety, Tolerance, Pharmacokinetic Characteristic of MAX-40279-01 in Patients With Advanced Solid Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Maxinovel Pty., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-40279-01 in patients with advanced solid tumor.

Detailed description

This is a two-part study comprised of a dose escalation part and a dose expansion part.

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	MAX-40279-01	Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria. Part 2: Dose expansion, Recommended doses from Part 1.

Timeline

• Start date: 2019-11-28
• Primary completion: 2022-11-01
• Completion: 2022-12-01
• First posted: 2019-12-03
• Last updated: 2022-01-19

Locations

1 site across 1 country: China